MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
- Known as:
- MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
- Catalog number:
- 10082-RP02
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
Related genes to: MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
- Gene:
- IMMP2L NIH gene
- Name:
- inner mitochondrial membrane peptidase subunit 2
- Previous symbol:
- IMMP2L-IT1
- Synonyms:
- IMP2
- Chromosome:
- 7q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-07-11
- Date modifiied:
- 2018-01-23
- Gene:
- MMP2 NIH gene
- Name:
- matrix metallopeptidase 2
- Previous symbol:
- CLG4, CLG4A
- Synonyms:
- TBE-1
- Chromosome:
- 16q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-05-25
- Date modifiied:
- 2015-02-23
- Gene:
- MMP15 NIH gene
- Name:
- matrix metallopeptidase 15
- Previous symbol:
- -
- Synonyms:
- MT2-MMP, MTMMP2, SMCP-2
- Chromosome:
- 16q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-11-13
- Date modifiied:
- 2016-10-05
- Gene:
- MMP23A NIH gene
- Name:
- matrix metallopeptidase 23A (pseudogene)
- Previous symbol:
- MMP21
- Synonyms:
- MIFR
- Chromosome:
- 1p36.33
- Locus Type:
- pseudogene
- Date approved:
- 1999-08-26
- Date modifiied:
- 2016-10-05
- Gene:
- MMP23B NIH gene
- Name:
- matrix metallopeptidase 23B
- Previous symbol:
- MMP22
- Synonyms:
- MIFR, MIFR-1
- Chromosome:
- 1p36.33
- Locus Type:
- gene with protein product
- Date approved:
- 1999-08-26
- Date modifiied:
- 2016-10-05
Related products to: MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
Related articles to: MMP_2 _ CLG4A Antibody (Antigen Affinity Purified)
- Pterygium is a common ocular surface disease characterized by a high recurrence rate and unknown etiology. - Source: PubMed
Publication date: 2025/01/16
Han ShichaoZhu WeiGuo Qianqian - Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) substantially contribute to the regulation of intercellular interactions and thereby play a role in maintaining the tissue structure and function. We examined methylation of a subset of 5'-cytosine-phosphate-guanine-3' (CpG) dinucleotides in promoter regions of the , , and genes by methylation-sensitive restriction enzyme digestion PCR. In our collection of 183 breast cancer samples, abnormal hypermethylation was observed for CpGs in , and promoter regions. The non-methylated status of the examined CpGs in promoter regions of , and in tumors was associated with low HER2 expression, while the group of samples with abnormal hypermethylation of at least two of these MMP genes was significantly enriched with HER2-positive tumors. Abnormal methylation of and was significantly associated with a CpG island hypermethylated breast cancer subtype discovered by genome-wide DNA bisulfite sequencing. Our results indicate that abnormal hypermethylation of at least several MMP genes promoters is a secondary event not directly functional in breast cancer (BC) pathogenesis. We suggest that it is elevated and/or ectopic expression, rather than methylation-driven silencing, that might link MMPs to tumorigenesis. - Source: PubMed
Publication date: 2020/05/10
Simonova Olga AKuznetsova Ekaterina BTanas Alexander SRudenko Viktoria VPoddubskaya Elena VKekeeva Tatiana VTrotsenko Ivan DLarin Sergey SKutsev Sergei IZaletaev Dmitry VNemtsova Marina VStrelnikov Vladimir V - By understanding Matrix Metalloprotease (MMP) dysregulation from a pan-cancer perspective, this study sheds light on the diagnostic potentials of MMPs across multiple neoplasms. - Source: PubMed
Publication date: 2019/06/14
Gobin EmilyBagwell KaylaWagner JohnMysona DavidSandirasegarane SharmilaSmith NathanBai ShanSharma AshokSchleifer RobertShe Jin-Xiong